Loading...
XSTOXVIVO
Market cap1.35bUSD
Dec 23, Last price  
473.00SEK
1D
1.39%
1Q
-5.31%
Jan 2017
437.50%
IPO
2,207.32%
Name

Xvivo Perfusion AB

Chart & Performance

D1W1MN
XSTO:XVIVO chart
P/E
162.27
P/S
24.93
EPS
2.91
Div Yield, %
0.00%
Shrs. gr., 5y
2.62%
Rev. gr., 5y
26.04%
Revenues
598m
+43.88%
14,724,00068,922,00084,702,000120,245,000138,177,000148,342,000187,868,000220,838,000179,861,000258,386,000415,292,000597,542,000
Net income
92m
+398.29%
-769,0008,054,0003,738,0005,131,0001,501,0006,260,00012,685,0004,939,000-43,735,0008,152,00018,427,00091,820,000
CFO
46m
+66.17%
1,669,00013,464,000-3,741,0008,578,00012,550,00022,190,00023,627,00029,505,000-12,266,000-12,059,00027,856,00046,287,000
Earnings
Jan 28, 2025

Profile

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
IPO date
Oct 08, 2012
Employees
142
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
597,542
43.88%
415,292
60.73%
258,386
43.66%
Cost of revenue
597,578
411,056
277,521
Unusual Expense (Income)
NOPBT
(36)
4,236
(19,135)
NOPBT Margin
1.02%
Operating Taxes
2,701
3,887
(1,487)
Tax Rate
91.76%
NOPAT
(2,737)
349
(17,648)
Net income
91,820
398.29%
18,427
126.04%
8,152
-118.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
429,250
447
245,353
BB yield
-4.35%
-0.01%
-3.04%
Debt
Debt current
10,268
5,550
4,199
Long-term debt
52,606
14,460
7,243
Deferred revenue
1,499
Other long-term liabilities
65,616
137,831
124,522
Net debt
(483,796)
(226,946)
(388,413)
Cash flow
Cash from operating activities
46,287
27,856
(12,059)
CAPEX
(43,015)
(130,946)
(94,074)
Cash from investing activities
(161,619)
(197,624)
(187,703)
Cash from financing activities
418,547
(6,842)
234,611
FCF
(129,061)
(64,034)
(30,455)
Balance
Cash
546,088
246,545
398,696
Long term investments
582
411
1,159
Excess cash
516,793
226,191
386,936
Stockholders' equity
181,263
116,297
32,120
Invested Capital
1,860,835
1,460,391
1,384,771
ROIC
0.02%
ROCE
0.26%
EV
Common stock shares outstanding
29,935
29,526
28,936
Price
329.50
80.05%
183.00
-34.29%
278.50
-11.31%
Market cap
9,863,631
82.55%
5,403,248
-32.95%
8,058,697
-5.55%
EV
9,379,835
5,176,302
7,670,284
EBITDA
30,827
46,403
13,122
EV/EBITDA
304.27
111.55
584.54
Interest
1,190
605
276
Interest/NOPBT
14.28%